People: Rexahn Pharmaceuticals, Inc. (RNN)

RNN on American Stock Exchange

0.75USD
9 Feb 2010
Price Change (% chg)

$0.06 (+8.70%)
Prev Close
$0.75
Open
--
Day's High
$0.82
Day's Low
$0.68
Volume
2,552,105
Avg. Vol
173,287
52-wk High
$2.00
52-wk Low
$0.40

view people for:

Summary

Name Age Since Current Position
Ahn, Chang Ho 57 2005 Chairman of the Board, Chief Executive Officer
Soni, Rakesh 53 2009 President, Chief Operating Officer
Jeong, Tae Heum 38 2005 Chief Financial Officer, Secretary, Director
Beever, Charles 56 2006 Director
Cheong, Kwang Soo 48 2006 Director
Kang, Y. Michele 49 2006 Director
McIntosh, David 50 2005 Director
Hoffman, Freddie 58 2007 Director
» Insider Trading

Biographies

Name Description
Ahn, Chang Ho Dr. Chang H. Ahn has served as Chairman of the Board, Chief Executive Officer and a Director of Rexahn Pharmaceuticals, Inc. since May 2005. Dr. Ahn served as Chairman and Chief Executive Officer of Rexahn, Corp from its incorporation in March 2001 to May 2005. From 1988 to 2001, Dr. Ahn held dual positions as both Expert Regulatory Pharmacologist and Lab Head at the FDA's Center for Drug Evaluation and Research. Prior to joining the FDA in 1988, Dr. Ahn carried out cancer research at the National Cancer Institute, as well as at Emory University's School of Medicine. In 2003 and 2004, Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, for which Maryland State and Montgomery County are partners. He also served as president of the Society of Biomedical Research from 2000 to 2003. Dr. Ahn holds a Ph.D. in pharmacology from Ohio State University. He also holds two B.S. degrees in pharmacy from Creighton University and Seoul National University.
Soni, Rakesh Mr. Rakesh Soni has been appointed as President, Chief Operating Officer of Rexahn Pharmaceuticals, Inc effective August 10, 2009. He has served as Chief Business Officer of Rexahn Pharmaceuticals, Inc since July 2008. He joined Rexahn with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held several leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, he has held a variety of management positions at Novartis and Schering-Plough. He is a member of the Healthcare Marketing Council, the Medical Marketing Association and Licensing Executives Society. Mr. Soni has a Bachelor of Science from University of Wisconsin, Madison and an Master of Business Administration from Fairleigh Dickinson University.
Jeong, Tae Heum Tae Heum Jeong has served as Chief Financial Officer, Secretary and Director since June 2005. Mr. Jeong served as Chief Financial Officer of Rexahn, Corp from December 2002 to May 2005. From 1997 to November 2002, Mr. Jeong served as a senior investment manager at Hyundai Venture Investment Corporation, a venture capital firm where he managed the biotech investment team. He was also a committee member of the Industrial Development Fund of Korea's Ministry of Commerce, Industry and Energy from 2000 to 2002. Mr. Jeong holds an M.S. in Finance from Johns Hopkins University, and a B.S. and an M.S., in Chemistry, from POSTECH.
Beever, Charles Charles Beever has served as a Director of Rexahn Pharmaceuticals, Inc. since May 2006. He has been a partner and Vice President of Booz Allen & Hamilton, Inc. since October 1993 to July 2008 and served as staff member and Engagement Manager at Booz Allen Hamilton from January 1984 to October 2003. Prior to joining Booz Allen Hamilton, Mr. Beever served as Plant Production Manager from October 1981 to January 1984, Industrial Engineering Manager from June 1979 to October 1981 and Production Supervisor from July 1978 to June 1979 at McGraw-Edison Company. Mr. Beever holds a B.A. in Economics from Haverford College, where he was elected to Phi Beta Kappa, and an M.B.A. from the Harvard Graduate School of Business Administration.
Cheong, Kwang Soo Kwang Soo Cheong has served as a Director of Rexahn Pharmaceuticals, Inc. since May 2006. He is a faculty member at the Department of Finance of the Johns Hopkins University Carey Business School (Assistant Professor: 2001-2005 & Associate Professor: 2006 to date). Dr. Cheong was an Assistant Professor of Economics at the University of Hawaii from 1994 to 2001, and he was a lecturer at the Department of Economics of Stanford University from 1993 to 1994. During the summer of 1995, Dr. Cheong was a Visiting Fellow in the Taxation and Welfare Division at the Korea Development Institute in Korea. Dr. Cheong holds a B.A. in Economics and an M.A. in Economics from Seoul National University, and a Ph.D. in Economics from Stanford University.
Kang, Y. Michele Y. Michele Kang has served as a Director of Rexahn Pharmaceuticals, Inc. since May 2006. She is currently Chief Executive Officer of Cognosante, a Health IT company founded in March 2008. She has been Vice President and General Manager of Northrop Grumman Information Technology's Health Solutions division since 2003; Vice President and Deputy General Manager, Global Information Technology of Northrop Grumman Mission Systems from 2001 to 2003; and Vice President, e-Business of Northrop Grumman Mission Systems from 2000 to 2001. She is a member of the eHealth Initiative Leadership Council and a member of the steering committee of Connecting for Health. Prior to joining Northrop Grumman, Ms. Kang was a partner in the Strategic Advisory Services group of Ernst & Young LLP. Ms. Kang received a B.A. in Economics from the University of Chicago and a Master's degree in Public and Private Management from the Yale School of Management.
McIntosh, David David McIntosh has served as a Director of Rexahn Pharmaceuticals, Inc. since May 2005. Mr. McIntosh served as a director of Rexahn, Corp from March 2004 to May 2005. He has been a partner at Mayer Brown LLP (law firm) since 2001. Mr. McIntosh was a member of the United States House of Representatives, representing the 2nd District of Indiana from 1995 to 2001. From 1993 to 1994, he was a director of the Hudson Institute Competitiveness Center. He served on President Bush's Council on Competitiveness as Executive Director from 1989 to 1993. He also served as the Special Assistant to President Reagan for Domestic Affairs from 1987 to 1989 and was the Special Assistant to the Attorney General of the United States from 1986 to 1987. Mr. McIntosh received a B.A. from Yale College and a J.D. from the University of Chicago Law School.
Hoffman, Freddie Dr. Freddie Ann Hoffman has served as a Director of Rexahn Pharmaceuticals, Inc. since June 2007. Dr. Hoffman is CEO of HeteroGeneity, LLC, a Washington-DC based consulting firm, which she founded in 2003. She served as Senior Medical Director for New Product Development for Pfizer Consumer Healthcare from 1999 to 2003. From 1986 until 1999, Dr. Hoffman served as Chief of the Cytokines, Growth Factors and Oncologic Products Branch, in the FDA Center for Biologics Evaluation and Review, where she was involved with the licensing of 15 biologic drugs. While at the FDA, she also served as deputy director of the Medicine Branch, within the Office of the FDA Commissioner. Before joining FDA, Dr. Hoffman completed a fellowship in pediatric hematology-oncology at the National Cancer Institute, where she spent a decade conducting clinical and laboratory research, and serving as Director of Extramural Clinical Trials in the Biological Response Modifiers Branch, NCI. She has a Bachelors of Science in Chemistry from UCLA, and a Medical Degree and general pediatric residency training from the University of California at Davis.

Basic Compensation

Name Fiscal Year Total
Ahn, Chang Ho 335,280
Soni, Rakesh 103,654
Jeong, Tae Heum 151,135
Beever, Charles --
Cheong, Kwang Soo --
Kang, Y. Michele --
McIntosh, David --
Hoffman, Freddie --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Ahn, Chang Ho 0 0
Soni, Rakesh 0 0
Jeong, Tae Heum 0 0
Beever, Charles 0 0
Cheong, Kwang Soo 0 0
Kang, Y. Michele 0 0
McIntosh, David 0 0
Hoffman, Freddie 0 0

Insider Trading

Name Shares Traded Price
MCINTOSH DAVID M 2,800 $0.80
MCINTOSH DAVID M 2,800 $0.80
AHN CHANG HO 2,600,000 $0.68
AHN CHANG HO 260,000 $0.68
AHN CHANG HO 400,000 $0.00
AHN CHANG HO 250,000 $0.00
SONI RAKESH 300 $5.97
CHEONG KWANG SOO 3,000 $2.25
KANG Y MICHELE 1,500 $2.35
KANG Y MICHELE 500 $2.35
KANG Y MICHELE 1,000 $2.35
KANG Y MICHELE 1,000 $2.35
KANG Y MICHELE 2,500 $2.30
KANG Y MICHELE 1,000 $2.35
KANG Y MICHELE 1,000 $2.35
KANG Y MICHELE 1,000 $2.30
KANG Y MICHELE 500 $2.25
JEONG TAE HEUM 1,300 $1.99
JEONG TAE HEUM 3,700 $2.35
AHN CHANG HO 4,000 $2.39
AHN CHANG HO 2,500 $2.45
HOFFMAN FREDDIE ANN 1,000 $2.20
AHN CHANG HO 1,000 $2.40
AHN CHANG HO 500 $2.20
AHN CHANG HO 2,000 $2.40
» Full list on Insider Trading
view people for: